La cadena de opciones muestra datos clave de las opciones de acciones de Phio Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Phio Pharma..

Phio Pharma (NASDAQ:PHIO) Bolsa, Cadena de Opciones

Phio Pharma

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHR

ATCH

ATPC

AVGR

CANG

CHCI

HCWC

LIDR

NMHI

PHIO

PIII

RGNX

RIME

SANG

STAF

URGN

YOSH

Las acciones de KB Home suben 9,1% tras superar expectativas de ganancias. Descubre los mayores ganadores y perdedores del mercado hoy.

Las acciones de KB Home se disparan un 9%; 20 acciones que se mueven en el premercado de EE.UU.

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharmaceuticals Corp

Press Releases

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

Aprea Therapeutics

BioCardia

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Ernexa Therapeutics

HCW Biologics

iBio

Immuron Limited - American Depositary Shares

Immuron

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Longeveron

Marker Therapeutics

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

OSR Holdings

Pelthos Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Comments

Phio Pharma

Phio Pharma (PHIO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL